Skip to main content


Fig. 1 | Clinical and Translational Medicine

Fig. 1

From: From fiction to science: clinical potentials and regulatory considerations of gene editing

Fig. 1

Ex vivo vs. in vivo gene editing. During ex vivo gene editing, the patient’s cells are removed from the body, genetically modified using gene editing components and then transferred back into the patient’s body. Alternatively, e.g. for allogeneic CAR T cell therapies, cells from healthy donors are genetically modified and then transferred into the patient. For in vivo gene editing, gene editing components are delivered directly to the patient’s cells using either viral or nonviral delivery systems

Back to article page